About This Show
Welcome to Doctor Thyroid with your host, Philip James.
This is a meeting place for you to hear from top thyroid doctors and healthcare professionals.
Information here is intended to help those wanting to 'thrive' regardless of setbacks related to thyroid cancer. Seeking good health information can be a challenge, hopefully this resource provides you with better treatment alternatives as related to endocrinology, surgery, hypothyroidism, thyroid cancer, functional medicine, pathology, and radiation treatment.
Not seeing an episode that addresses your particular concern? Please send me an email with your interest, and I will request an interview with a leading expert to help address your questions.
Philip James email@example.com.
Most Recent Episode
64: Managing Indeterminate Thyroid Nodules, with Dr. Kimberly Vanderveen from Denver Center for Endocrine Surgery
Kimberly Vanderveen, MD is a Colorado native and graduate of Bear Creek High School in Lakewood, CO. She received her bachelor’s degree with honors from Muhlenberg College in Allentown, PA. She then earned her medical degree from Northwestern University in Chicago, IL in 2001. Dr. Vanderveen completed her surgical residency at UC-Davis in Sacramento, CA. During her residency, she also obtained a master's degree in Clinical Research and was actively involved in cancer research and education. After her surgical training, Dr. Vanderveen completed a fellowship in Endocrine Surgery at the Mayo Clinic in Rochester, MN. She is knowledgeable in both medical and surgical aspects of endocrine diseases. She specializes in surgery for diseases of the thyroid, parathyroid, adrenal glands and is a high volume neck and adrenal surgeon. In this episode, the following topics are discussed: Two roads of tests: rule out and malignant markers Rule-out tests picks up innocent behavior pattern. Most common is Afirma Malignant markers, or rule-in tests, are useful at determining extent of surgery, and help avoid a second or third surgery. ThyroSeq, ThyraMIR, Rosetta Do patients get both tests? Rule out and behavior? Approximately 15% of FNA’s come back indeterminate. Some centers as high as 30% Managing indeterminate nodules when a patient chooses no surgery. Taking into account emotional, financial, and lifestyle goals of the patient. Addressing priorities and goals of the patients should come first. Additional molecular testing, surgery, or active surveillance. Profiling a patient who choose to remove thyroid even if indeterminate — is usually due to fear and the C word. Price of molecular test is $3000 - $6000 NOTES Kimberly Vanderveen, MD American Thyroid Associ